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Abstract
Background: In an effort to discover new drugs to treat tuberculosis (TB) we chose alanine racemase as the target of our
drug discovery efforts. In Mycobacterium tuberculosis, the causative agent of TB, alanine racemase plays an essential role in
cell wall synthesis as it racemizes L-alanine into D-alanine, a key building block in the biosynthesis of peptidoglycan. Good
antimicrobial effects have been achieved by inhibition of this enzyme with suicide substrates, but the clinical utility of this
class of inhibitors is limited due to their lack of target specificity and toxicity. Therefore, inhibitors that are not substrate
analogs and that act through different mechanisms of enzyme inhibition are necessary for therapeutic development for this
drug target.
Methodology/Principal Findings: To obtain non-substrate alanine racemase inhibitors, we developed a high-throughput
screening platform and screened 53,000 small molecule compounds for enzyme-specific inhibitors. We examined the ‘hits’
for structural novelty, antimicrobial activity against M. tuberculosis, general cellular cytotoxicity, and mechanism of enzyme
inhibition. We identified seventeen novel non-substrate alanine racemase inhibitors that are structurally different than any
currently known enzyme inhibitors. Seven of these are active against M. tuberculosis and minimally cytotoxic against
mammalian cells.
Conclusions/Significance: This study highlights the feasibility of obtaining novel alanine racemase inhibitor lead
compounds by high-throughput screening for development of new anti-TB agents.
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Introduction
Discovery and development of effective chemotherapeutic
agents for TB, a disease that affects one third of the world’s
population and kills 1–2 million people a year, is a top health
priority [1,2]. This need is further underscored by the lethal
synergy of TB and HIV epidemics, and the emergence of multiple
and extensively drug resistant (MDR and XDR) forms of the
disease that are difficult to treat with the existing drug regimen
[3,4,5,6,7,8]. Despite this need, no new drug classes have been
specifically marketed for TB in the last forty years [9], in part
owing to a lengthy and costly process that takes almost two
decades for drug approval [10]. One strategy that will allow for a
rapid path to new anti-TB agents is to discover new classes of
compounds against already validated drug targets.
In M. tuberculosis, one such target is alanine racemase (EC
5.1.1.1), a pyridoxal 59-phosphate (PLP)-containing enzyme
required for bacterial growth [11,12,13,14]. This enzyme catalyzes
the racemization of L-alanine to D-alanine, which is an essential
precursor for the pentapeptide cross-bridge of the peptidoglycan
layer in bacterial cell wall [15,16].
Due to its essential nature, coupled with the absence of a human
homolog, alanine racemase has long been an attractive drug
target. We have previously reported the crystal structure of the M.
tuberculosis alanine racemase [17]. The active form of the enzyme is
an obligatory dimer containing two monomers of 43 kDa in head-
to-tail orientation. Residues from both monomers contribute to
the two active sites, where PLP and alanine bind.
Most known enzyme inhibitors bind solely to the substrate-
binding region proximal to PLP. Shown in Figure 1, are several
well-known alanine racemase inhibitors. Cycloserine and o-
carbamyl-D-serine are two natural antibiotics known to inhibit
alanine racemase [18,19]. Only cycloserine has been developed
commercially for the treatment of TB, but its clinical utility is
limited due to toxicity issues arising from lack of target-specificity
[20]. By virtue of its primary amine, cycloserine inactivates alanine
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dependent enzymes are ubiquitous in nature, cycloserine is not
target-specific. Attempts to improve the activity or specificity
through alteration of the cycloserine ring of side chains have not,
to date, been successful [21,22]. Additional alanine racemase
inhibitors include b,b,b-trifluoroalanine, alanine phosphonate
[23], 1-amino-cyclopropane phosphonate [24] and b-chloro- and
b-fluoroalanine [25]. Like cycloserine, all of these inhibitors are
alanine analogs that contain primary amines, and as such, likely
will inhibit other PLP-dependent enzymes [26,27,28]. Therefore,
alanine racemase inhibitors that are not substrate analogs and
lacking primary amines in their structures are necessary for
therapeutic drug development.
Structure-guided drug design has been employed to identify
novel alanine racemase inhibitors [17,29,30,31]. Small molecules
in the 200–350 MW range have been successfully docked to the
active site [17,31]. These efforts, however, have not yet produced
strong inhibitors with antimicrobial activity against the TB
bacterium. The availability of a convenient alanine racemase
assay that is amenable for high-throughput screening (HTS) has
made it possible to screen for enzyme inhibitors. The overall aim
of this study was to optimize and utilize the alanine racemase assay
for HTS in search of novel enzyme inhibitors. Here, we report the
identification of several novel classes of alanine racemase inhibitors
that are not substrate analogs. Several of these inhibitors are active
against M. tuberculosis and show limited cytotoxicity against
mammalian cells. This study thus highlights the feasibility of
HTS as a rapid and effective approach to obtain novel alanine
racemase inhibitors for development as anti-TB agents.
Materials and Methods
Reagents
D-alanine, L-alanine, L-alanine dehydrogenase (Bacillus subtilis),
and b-NAD-sodium salt were purchased from Sigma Aldrich (St.
Louis, MO). Tricine and Tris were purchased from American
Bioanalytical. Recombinant M. tuberculosis alanine racemase was
expressed in E. coli as an N-terminal polyhistidine fusion. The
cloning, expression and purification of this recombinant enzyme
have been previously described [32].
Alanine racemase and L-alanine dehydrogenase assay
adaptation to 384-well format
The coupled alanine racemase assay of Esaki and Walsh [33],
which measures the racemization of D- to L-alanine, was adapted
to 384-well plate format. The assay was modified by varying the
concentrations of alanine racemase, D-alanine, NAD, and L-
alanine dehydrogenase in a Tricine buffer (100 mM, pH 8.5). The
optimized HTS assay reaction mixture consisted of 12 nM alanine
racemase, 1 mM NAD, 0.03 units/ml L-alanine dehydrogenase,
and 2.5 mM D-alanine in 100 mM Tris-Tricine. Forty microliters
of this reaction mixture were added to each well of a 384-well plate
(Corning 3710). After a 15-minute incubation, fluorescence
intensity associated with NADH, produced during the conversion
of the racemized alanine to pyruvate, was measured in an
EnVision plate reader (PerkinElmer, Waltham, MA) with
excitation/emission at 340/460 nm. A reaction cocktail without
the D-alanine substrate was used as the background control.
Assay components to measure the L-alanine dehydrogenase
coupling enzyme activity consisted of L-alanine, NAD, L-alanine
dehydrogenase and L-alanine in a Tris-Tricine buffer (100 mM,
pH 8.5). Concentrations of these components were varied
following the assay procedure described for the alanine racemase
assay. The HTS assay conditions consisted of 1 mM NAD, 0.01
units/ml L-alanine dehydrogenase, and 0.1 mM L-alanine in
100 mM Tris-Tricine buffer.
HTS procedures
Thirty microliters of the reaction cocktail containing 12 nM
alanine racemase, 1 mM NAD, 0.03 units/ml L-alanine dehy-
drogenase in 100 mM Tris-Tricine buffer, were transferred to
each well of a 384-well plate using an automated liquid dispenser
(WellMate, Matrix Technologies Corp., Hudson, NH). The plates
were loaded onto a pin transfer robot (Epson America Inc., Long
Beach, CA) and 0.1 ml of test substance (5 mg/ml stock for small
molecule compounds or 15 mg/ml natural product extracts) from
a master library plate was transferred to the test wells. After a 30-
minute incubation, 10 ml of 10 mM D-alanine (test and positive
control wells) or 10 ml of water (negative control wells) were added
to each well. NADH fluorescence intensity was measured in the
EnVision plate reader after incubation for 20 minutes.
The HTS procedure for the L-alanine dehydrogenase assay was
essentially as described for the alanine racemase assay. The
reaction cocktail containing 1 mM NAD and 0.03 units/ml L-
alanine dehydrogenase in 100 mM Tris-Tricine buffer was
incubated with 0.1 ml each test substance for 30 minutes. Enzyme
reactions were initiated by adding 10 ml of either 0.4 mM L-
alanine (test and positive control wells) or 10 ml of water (negative
control wells), and the reaction was read as described for the
alanine racemase assay.
Statistical significance of a positive signal was determined by
calculating the Z9-factor for each plate as described in [34], using
the following formula: Z9=12[3(SD signal+SD background)/(M
signal2M background)], where signal is the negative control and
background is the positive control, SD is the standard deviation,
and M is the mean.
Compound libraries
High-throughput screening was performed at the National
Screening Laboratory for Regional Centers of Excellence for
Biodefense and Emerging Infectious Diseases Research (NSRB) at
Harvard Medical School. The libraries of 53,000 small molecules
screened included therapeutic compounds approved by FDA,
purified natural products extracts, and compounds purchased from
BioMol TimTec (Plymouth Meeting, PA), Prestwick (Ilkirch,
France), ChemBridge (San Diego, CA), ENAMINE (Kiev,
Ukraine), Maybridge (Cornwall, UK), ChemDiv (San Diego, CA),
and MicroSource Diversity System’s NINDS custom collection
Figure 1. Substrate and selected inhibitors of alanine racemase. (A) alanine, (B) D-cycloserine, (C) o-carbamyl-D-serine, (D) L-alanine
phosphonic acid, (E) fluoro- or chloro-vinyl glycine, and (F) fluoro-alanine.
doi:10.1371/journal.pone.0020374.g001
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Institute and Harvard Medical School.
Enzyme IC50 determination
The HTS assay method was used for IC50 determination. Five-
fold dilution series of compounds (in DMSO) were prepared, and
added to 30 ml of reaction cocktail in 384-well plates to yield final
inhibitor concentrations of 5.7 mg/ml, 1.1 mg/ml, 229 ng/ml,
46 ng/ml, and 9 ng/ml. Each concentration was tested in
triplicate. After a 30-minute incubation, 10 ml of substrate was
added and fluorescence intensity was measured after a 20-minute
incubation. Percent inhibition at each inhibitor concentration
was calculated with respect to a negative control with no
inhibitor. The results were fitted onto a sigmoidal dose-response
curve using Prism software (GraphPad Software Inc., La Jolla,
CA) to calculate the IC50 (compound concentration that causes
50% inhibition).
Antimicrobial susceptibility studies against
M. tuberculosis
Antimicrobial activities of compounds were initially tested in the
BACTEC system (BD, Franklin Lakes, NJ) with MGIT 960
incubator/detector and BBL MGIT Mycobacteria Growth Indicator
tubes. Duplicate tubes were inoculated with a 1:500 dilution of M.
tuberculosis H37Rv suspension (turbidity of 0.5 McFarland
standard). The inhibitors, dissolved in dimethylsulfoxide (DMSO),
were added to each tube to a final concentration of 50 and
100 mg/ml. Appropriate controls included cycloserine as a positive
control for growth inhibition (50 and 100 mg/ml), and DMSO
solvent. The tubes were placed in the BACTEC MGIT 960
system and incubated at 37uC. Growth was monitored hourly for
42 days. In the BACTEC system, oxygen consumption by actively
respiring bacteria is detected as an increase in fluorescence of an
oxygen-quenched indicator, and no change in fluorescence
intensity between the first and the last day of the experiment
indicates growth inhibition.
Compounds that showed activity in the BACTEC system were
re-evaluated using the microbroth dilution method to determine
the minimal inhibitory concentrations (MICs) as we have
previously reported [35]. Ninety-six-well microtiter plates (Corn-
ing) were filled with 7H10 broth, pH 6.6. Six serial two-fold
dilutions of inhibitors (to yield final concentrations of 25, 12.5,
6.25, 3.125, 1.56 and 0.78 mg/ml) were added to appropriate wells
to which 5610
4 viable M. tuberculosis H37Rv were added. The
plates were incubated at 37uC and growth was visually inspected
after 21 days. The MIC was defined as the lowest concentration of
compound that did not yield visible turbidity. To determine the
effect of D-alanine, MIC experiments were performed with 5 mM
D-alanine in the growth medium.
Compound cytoxicity studies
HeLa cells were grown to confluence overnight (37uC, 5%
CO2) in Dulbecco’s Modified Eagle Medium with 10% fetal
bovine serum (Invitrogen, Carlsbad, CA). The following day,
3000 cells were plated into each well of a 96-well plate and grown
overnight. Compounds were diluted in culture medium and
added to the cells to yield final concentrations of 100, 50, 25,
12.5, and 6.25 mg/ml. The cells were exposed to the compounds
for 48 hours, after which the effect on cells was determined using
the WST-1 Cell Proliferation Reagent (Roche Applied Science,
Indianapolis, IN) according to manufacturer’s protocols. Absor-
bance at 450 nm was used to calculate percent cytotoxicity with
respect to a DMSO solvent control. The results were fitted onto a
sigmoidal dose-response curve using Prism software to calculate
the TC50 (compound concentration that causes 50% cell death).
Ki determination
For Ki determination, alanine racemase was incubated with
varying concentrations of inhibitors (0.98, 0.49, 0.43, 0.38, 0.31,
0.30, 0.29, 0.25, 0.17, 0.15, 0.10, 0.09, 0.08, 0.05, 0.01 mM). The
mixtures were aliquoted and varying concentrations of D-alanine
(2.5, 2, 1.5, 1, and 0.5 mM) in the reaction cocktail were added.
After a 10-minute incubation, absorbance of NADH at 340 nm
was read and enzyme velocity plots were generated. For each
inhibitor concentration, the reciprocal of the enzyme reaction
velocity versus the reciprocal of the substrate concentration was
plotted in a Lineweaver-Burk plot. Subsequently, in a secondary
plot, the slope at each inhibitor concentration (y=Km[inhibitor]/
V[inhibitor]) was plotted versus the concentration of the inhibitor (X-
axis). The data were fitted to a linear regression, and Ki was
determined from the intercept on the inhibitor axis. All assays
were performed in triplicate.
Electrospray ionizaton mass spectrometry
Electrospray ionization mass spectrometry (ESMS) was
performed to detect direct interactions of inhibitors with enzyme.
A mixture of 15 mlo fs a m p l e( 4 mMa l a n i n er a c e m a s ew i t h
1 mM inhibitors) was diluted with 15 ml 2% acetonitrile/0.1%
formic acid. Samples were then de-salted using C4 ZipTip,
eluted into 15 ml 60% acetonitrile/0.1% formic acid, and
directly injected into Qtof-micro MS instrument (Waters Corp.,
Milford, MA).
Results
Development of HTS assays to screen for M. tuberculosis
alanine racemase inhibitors
The two enzymatic assays developed for screening alanine
racemase-specific inhibitors are shown in Figure 2. The first assay
is based on the Esaki and Walsh reaction where the conversion of
D-alanine to L-alanine by alanine racemase is coupled to the
deamination of L-alanine to pyruvate by the NAD-dependent L-
alanine dehydrogenase (Figure 2A) [33]. The formation of NADH
from this reaction can be quantified fluorometrically following
excitation at 340 nm and emission at 460 nm. This coupled
reaction offers a convenient, cost-effective and straightforward
means to screen for alanine racemase inhibitors in a high-
throughput setting. One drawback of this assay however, is its
inability to discriminate inhibitors of the coupling enzyme. Since
the latter would result in high rates of false positives, it was
necessary to develop a second assay to identify inhibitors of the
coupling enzyme. Shown in Figure 2B, this assay essentially
consists of the second half of the coupled reaction and directly
measures the deamination of L-alanine to pyruvate.
The two assays were adapted from a 1-ml cuvette format to a
40-ml 384-well plate format and optimized for HTS. Varying
concentrations of substrates, enzymes and NAD co-factor were
tested to obtain conditions that would be suitable for HTS. The
optimized racemase assay yielded a reaction that proceeded
linearly over a 40-minute period with a signal-to-background ratio
of 10 (Figure 3A). The optimized coupled assay, yielded a reaction
that proceeded linearly over a 20-minute period with a signal-to-
background ratio of at least 10 (Figure 3B). For both assays, the
calculated values for signal-to-background ratio and the screening
window co-efficient (Z9 factor .0.7) indicated that the assays were
suitable for HTS [34].
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racemase inhibitors
The two assays were used to screen 53,000 synthetic compounds
and natural product extracts from 13 different libraries. The
libraries were screened in duplicate at final concentrations of
12.5 mg/ml for synthetic compounds and 37.5 mg/ml for natural
products. Reaction mixtures containing the enzymes were pre-
incubated with each test substance in 384-well plates. Positive and
negative controls (without inhibitor and substrate, respectively)
were included in each plate. After a 30-minute pre-incubation,
substrates were added and fluorescence intensity was read. The
percent inhibition for each test substance was calculated with
respect to the controls and the plots are shown in Figure 4. With
respect to the controls (Figure 4A), the majority of the 53,000
compounds did not show inhibition (Figure 4B). Compounds
showing greater than 30% inhibition in the alanine racemase assay
and less than 10% inhibition in the coupling enzyme assay were
designated ‘hits’. Based on these criteria, 472 compounds were
identified as hits for a hit-rate of 0.9%. All the hits were from
synthetic compound libraries. The hits were ranked for potency
based on percent inhibition of alanine racemase. As shown in
Figure 4C, there were 25 strong (.80%), 199 intermediate (51–
80%) and 248 weak (30–50%) alanine racemase inhibitors.
Further selection criteria for hits and determination of
alanine racemase IC50
Allthe HTS hits wereranked based on structure-based calculated
properties, giving priority to those with low molecular weights, high
inhibition potency, lower numbers of rotatable bonds, hydrogen
bond donors and acceptors, lower polar surface area, and lack of
highly reactive groups [36]. Based on this analysis, 167 hits were
cherry-picked and retested in a 5-fold dilution series (5.7, 1.1, 0.229,
0.046, 0.009 mg/ml). Sixteen of these compounds specifically
inhibited alanine racemase in a dose-dependent manner with more
than 50%inhibitionat the highestdose. Table 1 shows the chemical
structures of the 16 new alanine racemase inhibitors, which include
two hydrazides (L2-1 and 2), two pyrimidine carboxamides (L2-5
and 6), three thioamides (L2-7, 9, and 12), one each of hydroxamic
acid (L2-3), thiopyridine (L2-4), pyridine ester (L2-10), oxadiazole
N-oxide (L2-18), carbamodithioate (L2-11), isothiazolopyridione
(L2-13), benzopyranone oxime (L2-14), alkoxy phenol (L2-15), and
Figure 2. HTS assays for screening alanine racemase-specific inhibitors. (A) Coupled alanine racemase assay. (B) L-alanine dehydrogenase
coupling enzyme assay.
doi:10.1371/journal.pone.0020374.g002
Figure 3. Kinetics of alanine racemase and L-alanine dehydro-
genase activities in HTS format. (A) When converted to 384-well
plate format, the alanine racemase reaction gives a linear increase in
fluorescence over a 40-minute period (X) as compared to the
background control without substrate (m). (B) The L-alanine dehydro-
genase reaction gives a linear increase in fluorescence over a 20-minute
period (&) as compared to the background control without substrate
(X).
doi:10.1371/journal.pone.0020374.g003
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their enzyme IC50 values were determined. The results, summa-
rized in Table 1, show that the IC50 values rangedfrom 1 to 13 mM,
with the pyridine ester (L2-10) showing the most potent activity.
Antimicrobial activity of 16 new alanine racemase
inhibitors against M. tuberculosis
All compounds were screened for antimicrobial activity against
M. tuberculosis H37Rv. BACTEC culture tubes were inoculated
with M. tuberculosis H37Rv, and inhibitors were added to a final
concentration of 50 and 100 mg/ml. Cycloserine and DMSO
solvent were included as positive and negative controls, respec-
tively. The results are summarized in Table 1. Of the 16
compounds tested, seven compounds (L2-04, L2-05, L2-06, L2-10,
L2-12, L2-13, and L2-16) inhibited growth at both concentrations.
To corroborate these findings, we proceeded to determine the
minimal inhibitory concentrations (MIC) of the 7 active compounds
using the microbroth dilution method as we have previously
reported [35]. The results, which are summarized in Table 1, show
that the antimicrobial activities of all seven compounds were
confirmed. Their MICs ranged from ,1.56 to 12.5 mg/ml
(,4.5 mMt o5 9 mM), several of which were lower than the
6.5 mg/ml (65 mM) MIC of cycloserine. To determine if the
observed growth inhibition was due to inhibition of cellular alanine
racemase, we measured the MICs in the presence of 5 mM D-
alanine in the growth medium. While a 3-fold increase in the MIC
was observed for cycloserine, no significant increase was observed
for any of the seven inhibitors, suggesting that their antimicrobial
activity might not due solely to inhibition of cellular alanine
racemase (data not shown).
Cytotoxicity studies of seven alanine racemase inhibitors
with antimicrobial activity
We proceeded to examine the cytotoxicity of the seven active
compounds in a mammalian cell line. HeLa cells were exposed to
varying concentrations of the seven compounds for 48 hours. The
effects of the compounds on cellular viability were determined by
measuring mitochondrial activity in live cells. The TC50 value
(compound concentration that causes 50% cell death) of each
compound is shown in Table 1. The values for the seven
compounds ranged from 33–406 mM while the TC50 of
cycloserine was 203 mM. Therapeutic indices (Ti) of the
compounds were calculated to gauge the suitability of the
compounds as potential leads. The results, which are summarized
Figure 4. Summary of HTS outcome. (A) Results of positive and negative controls plotted for 367 representative wells of the alanine racemase
assay. The positive control represents 100% inhibition (wells 1–176) and the negative control represents 0% inhibition in the presence of 1% DMSO
(wells 177–367). (B) HTS data for one of the two replicates for the entire 53,000-compound screen, obtained from 138 384-well plates. The line
indicates the 30% inhibition cut-off for hit selection. A similar distribution of positive and negative controls results were obtained for the coupling
enzyme assay (data not shown). (C) Distribution of the 267 hits, with the hits categorized into 7 groups with respect to percent inhibition.
doi:10.1371/journal.pone.0020374.g004
Table 1. Chemical properties and activities of new alanine racemase inhibitors and cycloserine*.
Hits Inhibitor MW
IC50
mM
1Mtb
2MIC
mM
3TC50
mM
4Ti
Ki
mM
L2-01 N9,N9,4-trimethylbenzenesulfonohydrazide 214 9.0 2 ND ND ND ND
L2-02 2-N9,2-N9,7-N9,7-N9-tetramethyl-9H-fluorene-2,7-disulfonohydrazide 410 1.6 2 ND ND ND ND
L2-03 N-hydroxy-2-(2-hydroxyphenoxy)acetamide 183 8.2 2 ND ND ND ND
L2-04 ethyl 3-(pyridin-2-ylthio)propanoate 211 2.6 + 59 229.8 4 0.038
L2-05 N-benzyl-5-chloro-2-methylsulfonylpyrimidine-4-carboxamide 326 6.8 + 9 20 2 0.63
L2-06 5-chloro-N-(3-chloro-4-methoxyphenyl)2(methylsulfonyl)pyrimidine-
4carboxamide
346 8.2 + ,4.5 18.8 4 0.76
L2-07 2-(4-methylphenyl)-1-morpholin-4-ylethanethione 235 6.5 2 ND ND ND ND
L2-09 2-(4-methoxyphenyl)-1-morpholin-4-ylethanethione 251 3.3 2 ND ND ND ND
L2-10 6-O-[3-chloro-4-(6-methoxycarbonylpyridine-2-carbonyl)oxyphenyl]
2-O-methyl pyridine-2,6-dicarboxylate
471 1.0 + 13.6 157.2 12 0.68
L2-11 2-(pyridin-3-ylcarbamothioyl sulfanyl)acetic acid 228 13.1 2 ND ND ND ND
L2-12 2-phenyl-1-piperidin-1-ylethanethione 219 6.0 + 28.6 406 14 0.08
L2-13 2-(4,6-dimethyl-3-oxo-[1,2]thiazolo[5,4-b]pyridin-2-yl)-N-[2-(4-
ethoxyphenyl)ethyl]acetamide
384 7.7 + 16.2 36.4 2 0.93
L2-14 2-(hydoxyimino)-6-methyl-2H-benzopyran-3-carboxamide 208 2.8 2 ND ND ND ND
L2-15 2-(2-hydroxyphenoxy)-N-methylacetamide 181 5.7 2 ND ND ND ND
L2-16 3,3-dihydroxy-1H-quinoline-2,4-dione 193 5.2 + 32.4 33.7 1 0.02
L2-18 1,19-(2-oxido-1,2,5-oxadiazole-3,4-diyl)-bis (1-(2-thienyl))-methanone 288 4.9 2 ND ND ND ND
CS (4R)-4-amino-3-isoxazolidinone 102 58 + 65 203 3 0.086
1antimicrobial activity against M. tuberculosis (+ active, 2 inactive);
2MIC against M. tuberculosis;
3Cytotoxicity in HeLa cells,
4Ti=TC50/MIC, ND- not determined; CS- cycloserine.
*Chemical structures of inhibitors are provided in Table S1.
doi:10.1371/journal.pone.0020374.t001
Novel Alanine Racemase Inhibitors
PLoS ONE | www.plosone.org 6 May 2011 | Volume 6 | Issue 5 | e20374in Table 1, indicated that with the exception of L2-16, which was
cytotoxic at slightly above its MIC (Ti=1), the remaining
compounds did not show cytotoxicity at their respective MICs,
suggesting their suitability as potential leads.
Enzyme affinity (Ki) of seven alanine racemase inhibitors
with antimicrobial activity
Next we determined the enzyme affinity of the seven inhibitors.
For Ki determination, enzyme activity was measured at 15
different inhibitor concentrations (0.01 to 0.98 mM) and at five
different substrate concentrations (0.5–2.5 mM). As shown in
Table 1, the Ki values of the seven compounds ranged from 0.038
to 0.927 mM.
Analysis of inhibitor enzyme interaction by mass
spectrometry
Since the coupled enzyme assay does not reveal direct
interaction of inhibitors with alanine racemase, we used mass
spectrometry to detect if actual binding occurred and if so, the
nature of the binding. Mixtures of alanine racemase with each of
the seven inhibitors, cycloserine, and alanine were analyzed by
ESMS and the results are shown in Figure 5. Under these
conditions, the unmodified monomeric enzyme has two peaks
corresponding to molecular weights 43,702 and 43,721. In the
presence of alanine, L2-04, and L2-16 the peaks remain
unchanged, suggesting that like the substrate, these two inhibitors
likely interact with the enzyme in a reversible manner. In the
presence of the irreversible inhibitor cyloserine, the monomeric
peaks disappear with concomitant appearance of higher and lower
molecular weight peaks, indicating irreversible modification of the
enzyme. Similar results were observed with L2-05, L2-06, L2-12
and L2-13, suggesting that these inhibitors interact with the
enzyme in an irreversible manner. The results for L2-10, however,
were not definitive as the peak profile was ambiguous. Further
studies are currently underway to elucidate the structural basis and
mode of action of these inhibitors.
Discussion
As an essential and uniquely prokaryotic enzyme, alanine
racemase has long been pursued as a target for antimicrobial drug
discovery. Numerous enzyme inhibitors have been identified. The
vast majority, however, are suicide substrates that react with the
enzyme cofactor and tend to indiscriminately inhibit other PLP-
containing enzymes. In an effort to obtain more target-specific
inhibitors, we performed HTS and identified 16 novel alanine
racemase inhibitors that are not substrate analogs. A subset of
these inhibitors blocked M. tuberculosis growth and showed low
cytotoxicity toward mammalian cells, making them promising
leads and warranting further studies into their mechanism of
action.
Mass spectromentry analysis revealed that two of the inhibitors
likely bind the enzyme in a reversible manner while four inhibitors
are irreversible binders. It is highly unlikely that the inhibitors bind
the enzyme through interaction with PLP, primarily due to a
missing free amino group, requisite for external aldimine
formation with the co-factor [28]. Based on the crystal structure
of M. tuberculosis alanine racemase, there are at least three possible
ways by which an inhibitor that does not engage the PLP could
block enzyme function. An inhibitor could directly bind to the
active site, or alternatively, it could block the formation of the
active sites by blocking enzyme dimerization. All of these
possibilities are currently being investigated with efforts to obtain
enzyme-inhibitor co-crystals.
Some additional comments can be made concerning structure-
activity relationships (SAR) among the inhibitors in Table 1;
however, given the relatively small data set such SAR proposals
should be considered preliminary at this time. In any event, among
the three thioamides (L2-7, L2-9, and L2-12), whereas they all had
similar alanine racemase enzyme IC50s, only compound L2-12
had significant activity against M. tuberculosis in cell culture. This
would suggest that either a hydrogen on the para position of the
phenyl ring is favored over a methyl or methoxy group, or a
piperidine amide rather than a morpholine amide is necessary for
MICs, or both. Note that another thioketo derivative, namely the
carbamothioyl analog L2-11, had activity against alanine race-
mase; however, it did not show significant M. tuberculosis activity.
With regards to the two pyrimidine carboxamide derivatives L2-
05 and L2-06, while both had similar activity against the enzyme,
it would appear that more potent MIC activity is obtained with
L2-06 suggesting that a phenyl amide is preferred over a benzyl
amide for best cell culture activity. Inhibitors L2-01 and L2-02 are
both sulfonylhydrazides, with L2-02 showing significantly im-
proved alanine racemase enzyme inhibition over L2-01 suggesting
that either the larger size of L2-02 is allowing for additional
hydrophobic (possible p-stacking) interactions relative to L2-01, or
else the additional sulfonylhydrazide in L2-02 is responsible for
another favorable interaction with alanine racemase. The phenols
L2-03 and L2-15 may share a similar binding site in the enzyme,
and, if so, this would suggest that the methyl amide can be
replaced with a hydroxamide without significant loss of enzyme
activity. As more data is obtained on newer analogs of compounds
in Table 1, these preliminary SAR suggestions will likely be both
refined and expanded.
The antimycobacterial activities noted for seven of the inhibitors
are particularly encouraging, and highlight the feasibility of
obtaining, by HTS, not only structurally new alanine racemase
inhibitors, but also compounds that are able to cross the
mycobacterial cell wall. The seven inhibitors show good MICs,
which range from ,4.5 mMt o5 9 mM. However, preliminary
experiments with exogenously added D-alanine suggest that the
observed MICs may not be due solely to inhibition of alanine
racemase, and that additional cellular targets for these inhibitors
likely exist.
Cytotoxicity, which is often used as a criterion to select
compounds for lead development revealed that six inhibitors,
with the exception of L2-16, were not cytotoxic at their MIC
concentrations. The thioamide L2-12, though not cytotoxic, is
generally not considered a good therapeutic lead due to its
potential oxidation into toxic reactive species in vivo. This leaves
five new inhibitors as possible leads for further studies.
Conclusion
Alanine racemase has often been proposed as a target for drug
design in antimicrobial development. Though several attempts
have been made to rationally design enzyme inhibitors, none has
produced candidates superior to cycloserine, the toxic TB drug
that interacts with the PLP cofactor and blocks enzyme activity in
a non-specific manner. To identify inhibitors that do not share
features of cycloserine or any other previously known alanine
racemase inhibitors, we performed HTS of chemical compound
libraries. We identified several novel non-substrate alanine
racemase inhibitors. These belong to different chemical classes,
including hydrazide, hydroxamic acid, thiopyridine, pyrimidine
carboxamide, thioamide, pyridine ester, oxadiazole N-oxide,
carbamodithioate, isothiazolopyridione, benzopyranone oxime,
alkoxy phenol, and quinolinedione. Seven of these compounds
inhibited M. tuberculosis growth, several of which were minimally
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PLoS ONE | www.plosone.org 7 May 2011 | Volume 6 | Issue 5 | e20374Figure 5. Electrospray ionization mass spectrometry analysis of enzyme-inhibitor interaction. Alanine racemase (4 mM) and inhibitors or
substrate (1 mM) mixtures were analyzed by ESMS. Arrowheads indicate the peaks corresponding to monomeric alanine racemase.
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using HTS to obtain novel alanine racemase inhibitors that are
potentially useful for development as anti-TB agents.
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